Published in Int J Cancer on January 15, 2006
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene (2007) 3.17
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol (2010) 1.54
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer (2008) 1.30
The biology of progesterone receptor in the normal mammary gland and in breast cancer. Mol Cell Endocrinol (2011) 1.19
A systems biology view of cancer. Biochim Biophys Acta (2009) 1.17
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res (2008) 1.15
Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Front Oncol (2013) 1.14
VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase. FASEB J (2008) 1.14
Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Res (2013) 1.12
FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res (2010) 1.11
PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. Br J Cancer (2007) 1.02
Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Res (2008) 1.01
COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer (2010) 0.99
Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol (2013) 0.96
Clinical significance of pAKT and CD44v6 overexpression with breast cancer. J Cancer Res Clin Oncol (2010) 0.91
Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist (2014) 0.89
A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia (2008) 0.88
Phosphorylation status of Akt and caspase-9 in gastric and colorectal carcinomas. Int J Clin Exp Pathol (2014) 0.86
AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies. Breast Cancer Res Treat (2012) 0.85
Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Int J Oncol (2012) 0.84
Identification of a potent herbal molecule for the treatment of breast cancer. BMC Cancer (2009) 0.84
Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer. Cancer Med (2013) 0.82
Molecular mechanisms regulating the hormone sensitivity of breast cancer. Cancer Sci (2014) 0.82
The prognostic value of phosphorylated Akt in breast cancer: a systematic review. Sci Rep (2015) 0.82
Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine. Cancer Lett (2006) 0.81
Down-regulation of Gab1 inhibits cell proliferation and migration in hilar cholangiocarcinoma. PLoS One (2013) 0.80
Headway in resistance to endocrine therapy in breast cancer. J Thorac Dis (2010) 0.80
Early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. Surg Today (2013) 0.79
Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. Transl Oncol (2016) 0.79
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Virchows Arch (2016) 0.78
Review on molecular and chemopreventive potential of nimbolide in cancer. Genomics Inform (2014) 0.78
Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy. Oncogenesis (2014) 0.77
Molecular targets of breast cancer: AKTing in concert. Breast Cancer (Auckl) (2008) 0.77
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs (2016) 0.77
Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival. Breast Cancer (Auckl) (2014) 0.77
Calmodulin binds HER2 and modulates HER2 signaling. Biochim Biophys Acta (2010) 0.76
Detection of pAkt protein in imprint cytology of invasive breast cancer: Correlation with HER2/neu, hormone receptors, and other clinicopathological variables. Cytojournal (2015) 0.75
Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients. PLoS One (2017) 0.75
Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. Oncol Lett (2015) 0.75
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Sci Rep (2017) 0.75
Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer. Surg Today (2010) 0.75
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol (2012) 4.19
CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell (2011) 3.41
Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci (2009) 3.39
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol (2013) 3.26
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol (2010) 2.73
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol (2013) 2.45
Advantages of totally laparoscopic distal gastrectomy over laparoscopically assisted distal gastrectomy for gastric cancer. Surg Endosc (2009) 2.41
Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology (2006) 2.33
Colorectal cancer screening with odour material by canine scent detection. Gut (2011) 2.23
Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg (2006) 2.21
MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res (2009) 2.17
Obstructing spontaneous major shunt vessels is mandatory to keep adequate portal inflow in living-donor liver transplantation. Transplantation (2013) 2.14
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol (2011) 2.07
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res (2010) 2.05
Bile duct adenoma and von Meyenburg complex-like duct arising in hepatitis and cirrhosis: pathogenesis and histological characteristics. Pathol Int (2014) 2.01
Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res (2005) 1.99
Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res (2006) 1.89
Clinical significance and potential of hepatic microRNA-122 expression in hepatitis C. Liver Int (2010) 1.86
Involvement of autophagy in trypsinogen activation within the pancreatic acinar cells. J Cell Biol (2008) 1.85
Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol (2012) 1.84
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer (2011) 1.81
Prognostic nutritional index predicts outcomes of gastrectomy in the elderly. World J Surg (2012) 1.79
Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets (2008) 1.75
Physical activity and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci (2006) 1.72
A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg (2014) 1.65
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res (2006) 1.64
Risk factors for and management of delayed intraperitoneal hemorrhage after pancreatic and biliary surgery. Am J Surg (2007) 1.64
Diabetic microangiopathy in ischemic limb is a disease of disturbance of the platelet-derived growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors. Circ Res (2005) 1.64
Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats. Crit Care Med (2004) 1.62
Association between arterial stiffness and cerebral white matter lesions in community-dwelling elderly subjects. Hypertens Res (2008) 1.60
Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer (2011) 1.60
Long-term results of balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: a 10-year experience. J Gastroenterol Hepatol (2008) 1.59
Reconstruction of the middle hepatic vein tributaries using the recipient's recanalized umbilical vein in right-lobe living-donor liver transplantation. Surgery (2006) 1.58
Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res (2004) 1.58
Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer (2006) 1.57
Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery (2008) 1.57
Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. Pancreas (2006) 1.56
Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg (2013) 1.56
Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer (2012) 1.55
Risk factors that increase mortality after living donor liver transplantation. Transplantation (2012) 1.51
Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation (2008) 1.51
Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer (2010) 1.49
Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int (2014) 1.49
Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation. J Hepatol (2010) 1.48
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med (2012) 1.47
Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology (2010) 1.47
Ectopic pleural thymoma presenting as a giant mass in the thoracic cavity. Ann Thorac Surg (2007) 1.47
Long interspersed nucleotide element 1 hypomethylation is associated with poor prognosis of lung adenocarcinoma. Ann Thorac Surg (2013) 1.46
The changes of the medial right lobe, transplanted with left lobe liver graft from living donors. Transplantation (2009) 1.42
Sprouty2 and Sprouty4 are essential for embryonic morphogenesis and regulation of FGF signaling. Biochem Biophys Res Commun (2006) 1.41
Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer. Cancer Biol Ther (2010) 1.41
Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child. Pediatr Transplant (2007) 1.40
Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer (2005) 1.39
Inhibition of DNA binding of Sox2 by the SUMO conjugation. Biochem Biophys Res Commun (2006) 1.38
Selection of a right posterior sector graft for living donor liver transplantation. Liver Transpl (2014) 1.38
Is an elderly recipient a risk for living donor adult liver transplantation? Hepatogastroenterology (2008) 1.38
Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute's experience with 625 patients. J Am Coll Surg (2007) 1.37
Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg (2009) 1.35
MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol (2012) 1.35
Spreds are essential for embryonic lymphangiogenesis by regulating vascular endothelial growth factor receptor 3 signaling. Mol Cell Biol (2007) 1.34
MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) (2010) 1.33
Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology (2007) 1.33
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. Cancer Metastasis Rev (2012) 1.32
Indications for EMR/ESD in cases of early gastric cancer: relationship between histological type, depth of wall invasion, and lymph node metastasis. Gastric Cancer (2007) 1.32
Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet (2012) 1.32
CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci (2009) 1.32
PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res (2013) 1.31
Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol (2010) 1.31
CD44s regulates the TGF-β-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res (2012) 1.31
The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol (2007) 1.30
Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol (2006) 1.30
Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. Eur J Hum Genet (2010) 1.30
Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res (2005) 1.29
Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection: a multi-institutional study of the indications for resection. Hepatogastroenterology (2003) 1.29
Living donor liver transplantation in a patient with giant hepatic hemangioma complicated by Kasabach-Merritt syndrome: report of a case. Surg Today (2008) 1.28